Design, synthesis, and in vitro evaluation of novel aminomethyl-pyridines as DPP-4 inhibitors

ACS Medicinal Chemistry Letters

Volumn 1, Issue 9, 2010, Pages 530-535

  Kaczanowska, Katarzyna ^a   Wiesmüller, Karl Heinz ^a   Schaffner, Arnaud Pierre ^a  

^a EMC MICROCOLLECTIONS GMBH   (Germany)

Author keywords

Aminomethyl pyridines; diabetes; DPP 4; DPP 8; incretins; structureactivity relationship

Indexed keywords

5 AMINOMETHYL 4 (2,4 DICHLOROPHENYL) 6 METHYL PYRIDINE 2 CARBOXYLIC ACID CYANOMETHYL AMIDE; AMINE; DIPEPTIDYL PEPTIDASE IV INHIBITOR; ISOLEUCINE THIAZOLIDIDE; PYRIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MAMMAL CELL; PRIORITY JOURNAL;

MAMMALIA;

EID: 78650192270     PISSN: None     EISSN: 19485875     Source Type: Journal    
DOI: 10.1021/ml100200c     Document Type: Article

References (30)

1. Lambeir, A. M.; Durinx, C.; Scharpé, S.; De Meester, I. Dipeptidyl-peptidase IV from bench to bedside: An update on structural properties, functions, and clinical aspects of the enzyme DPP IV Crit. Rev. Clin. Lab. Sci. 2003, 40, 209-294
2. Durinx, C.; Lambeir, A. M.; Bosmans, E.; Falmagne, J. B.; Berghmans, R.; Haemers, A.; Scharpé, S.; De Meester, I. Molecular characterization of dipeptidyl peptidase activity in serum: Soluble CD26/dipeptidyl peptidase IV is responsible for the release of X-Pro dipeptides Eur. J. Biochem. 2000, 267, 5608-5613
3. Christopherson, K. W.; Hangoc, G.; Broxmeyer, H. E. Cell surface peptidase CD26/dipeptidylpeptidase IV regulates CXCL12/stromal cell-derived factor-1 alpha-mediated chemotaxis of human cord blood CD34+ progenitor cells J. Immunol. 2002, 169, 7000-7008
4. Havale, S. H.; Pal, M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes Bioorg. Med. Chem. 2009, 17, 1783-1802
5. Mohler, M. L.; He, Y.; Wu, Z.; Hwang, D. J.; Miller, D. D. Recent and Emerging Anti-DiabetesTargets Med. Res. Rev. 2009, 29, 125-195
6. Chia, C. W.; Egan, J. M. Incretin-Based Therapies in Type 2 Diabetes Mellitus J. Clin. Endocrinol. Metab. 2008, 93, 3703-3716
7. Drucker, D. J. Dipeptidyl Peptidase-4 Inhibition and the Treatment of Type 2 Diabetes. Preclinical biology and Mechanisms of Action Diabetes Care 2007, 30 (6) 1335-1343
8. Geelhoed-Duijvestijn, P. H. Incretins: A new treatment option for type 2 diabetes? Neth. J. Med. 2007, 65, 60-64
9. Thornberry, N. A.; Weber, A. E. Discovery of JANUVIA (Sitagliptin), a Selective Dipeptidyl Peptidase IV Inhibitor for the Treatment of Type2 Diabetes Curr. Top. Med. Chem. 2007, 7, 557-568
10. Pratley, R. E.; Jauffret-Kamel, S.; Galbreath, E.; Holmes, D. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes Horm. Metab. Res. 2006, 38, 423-428
11. Richter, B.; Bandeira-Echtler, E.; Bergerhoff, K.; Lerch, C. L. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus Cochrane Database Syst. Rev. 2008, 16, CD006739
12. Sebokova, E.; Christ, A. D.; Boehringer, M.; Mizrahi, J. Dipeptidyl Peptidase IV Inhibitors: The Next Generation of New Promising Therapies for the Management of Type 2 Diabetes Curr. Top. Med. Chem. 2007, 7, 547-555
13. Mulakayala, N.; Reddy, Ch. U.; Pal, M. Synthesis of dipeptidyl peptidase-4 inhibitors Tetrahedron 2010, 66, 4919-4938
14. Van der Veken, P.; Haemers, A.; Augustyns, K. Prolyl Peptidases Related to Dipeptidyl Peptidase IV: Potential of Specific Inhibitors in Drug Discovery Curr. Top. Med. Chem. 2007, 7, 621-635
15. Connolly, B. A.; Sanford, D. G.; Chiluwal, A. K.; Healey, S. E.; Peters, D. E.; Dimare, M. T.; Wu, W.; Liu, Y.; Maw, H.; Zhou, Y.; Li, Y.; Jin, Z.; Sudmeier, J. L.; Lai, J. H.; Bachovchin, W. W. Dipeptide Boronic Acid Inhibitors of Dipeptidyl Peptidase IV: Determinants of Potency and in Vivo Efficacy and Safety J. Med. Chem. 2008, 51, 60056013
16. Kang, N. S.; Ahn, J. H.; Kim, S. S.; Chae, C. H.; Yoo, S. E. Docking-based 3D-QSAR study for selectivity of DPP4, DPP8, and DPP9 inhibitors Bioorg. Med. Chem. Lett. 2007, 17, 3716-3721
17. Burkey, B. F.; Hoffmann, P. K.; Hassiepen, U.; Trappe, J.; Juedes, M.; Foley, J. E. Adverse effects of dipeptidyl peptidases 8 and 9 inhibition in rodents revisited Diabetes, Obes. Metab. 2008, 10, 1057-1061
18. Kuhn, B.; Hennig, M.; Mattei, P. Molecular recognition of ligands in dipeptidyl peptidase IV Curr. Top. Med. Chem. 2007, 7, 609-619
19. Lorey, S.; Stöckel-Maschek, A.; Faust, J.; Brandt, W.; Stiebitz, B.; Gorrell, M. D.; Kähne, T.; Mrestani-Klaus, C.; Wrenger, S.; Reinhold, D.; Ansorge, S.; Neubert, K. Different modes of dipeptidyl peptidase IV (CD26) inhibition by oligopeptides derived from the N-terminus of HIV-1 Tat indicate at least two inhibitor binding sites Eur. J. Biochem. 2003, 270, 2147-2156
20. Lee, H. J.; Chen, Y. S.; Chou, C. Y.; Chien, C. H.; Lin, C. H.; Chang, G. G.; Chen, X. Investigation of the dimer interface and substrate specificity of prolyl dipeptidase DPP8 J. Biol. Chem. 2006, 281, 38653-38662
21. Liang, G. B.; Qian, X.; Biftu, T.; Singh, S.; Gao, Y. D.; Scapin, G.; Patel, S.; Leiting, B.; Patel, R.; Wu, J.; Zhang, X.; Thornberry, N. A.; Weber, A. E. Discovery of new binding elements in DPP-4 inhibition and their applications in novel DPP-4 inhibitor design Bioorg. Med. Chem. Lett. 2008, 13, 3706-3710
22. Schaffner, A.-P.; Kaczanowska, K.; Baechle, D. Substituted pyridines as inhibitors of dipeptidyl peptidase IV and their application for treatment of diabetes and related diseases. EP 09012781.2.
23. Kaczanowska, K.; Eickhoff, H.; Albert, K.; Wiesmüller, K.-H.; Schaffner, A.-P. A Simple, Diversity Oriented Synthesis of Highly Substituted Pyridines. J. Heterocycl. Chem. 2010, in press.
24. Peglion, J.-L.; Poitevin, C.; Mannoury La Cour, C.; Dupuis, D.; Millan, M. J. Modulations of the amide function of the preferential dopamine D3 agonist (R,R)-S32504: Improvements of affinity and selectivity for D3 versus D2 receptors Bioorg. Med. Chem. Lett. 2009, 19, 2133-2138
25. Bemis, J. E.; Vu, C. B.; Xie, R.; Nunes, J. J.; Yee, Ng, P.; Disch, J. S.; Milne, J. C.; Carney, D. P.; Lynch, A. V.; Jin, L.; Smith, J. J.; Lavu, S.; Iffland, A.; Jirousek, M. R.; Perni, R. B. Discovery of oxazolo[4,5-b]pyridines and related heterocyclic analogs as novel SIRT1 activators Bioorg. Med. Chem. Lett. 2009, 19, 2350-2353
26. Khurana, J. M.; Kukreja, G. Rapid reduction of nitriles to primary amines with nickel boride at ambient temperature Synth. Commun. 2002, 32, 1265-1269
27. Dixon, M.; Webb, E. C. Enzymes, 2 nd ed.; Longman: London, 1971.
28. Van der Veken, P.; De Meester, I.; Dubois, V.; Soroka, A.; Van Goethem, S.; Maes, M.-B.; Brandt, I.; Lambeir, A.-M.; Chen, X.; Haemers, A.; Scharpé, S.; Augustyns, K. Inhibitors of dipeptidyl peptidase 8 and dipeptidyl peptidase 9. Part 1: Identification of dipeptide derived leads Bioorg. Med. Chem. Lett. 2008, 18, 4154-4158
29. Kleymann, G.; Werling, H. O. A Generally Applicable, High-Throughput Screening-Compatible Assay to Identify, Evaluate, and Optimize Antimicrobial Agents for Drug Therapy J. Biomol. Screening 2004, 9, 578-587
30. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings Adv. Drug Delivery Rev. 1997, 23, 3-25